Logo image
Chlorhexidine gluconate or polyhexamethylene biguanide disc dressing to reduce the incidence of Central-Line-Associated Blood Stream Infection: a feasibility randomised controlled trial (the CLABSI trial)
Journal article   Open access   Peer reviewed

Chlorhexidine gluconate or polyhexamethylene biguanide disc dressing to reduce the incidence of Central-Line-Associated Blood Stream Infection: a feasibility randomised controlled trial (the CLABSI trial)

Joan Webster, Emily Larsen, Nicole Marsh, Md Abu Choudhury, Patrick Harris and Claire M Rickard
Journal of Hospital Infection, Vol.96(3), pp.223-228
2017
pdf
PDF - Author's Accepted Version399.22 kBDownloadView
Accepted VersionPDF - Author Accepted Version Open Access
url
https://doi.org/10.1016/j.jhin.2017.04.009View
Published Version

Abstract

catheter-related infections randomised controlled trial feasibility studies chlorhexidine polyhexamethylene biguanide
Background: A number of antimicrobial impregnated discs to prevent central-line associated blood stream infection (CLABSI) are marketed but it is unclear which disc is most effective. Aim: To investigate the feasibility and safety of comparing two antimicrobial impregnated discs to prevent CLABSI. Methods: We conducted a single-centre, parallel group, randomised controlled trial in a 929-bed, tertiary referral hospital. Hospital in-patients requiring a peripherally inserted central catheter were randomised to chlorhexidine gluconate (CHG) or polyhexamethylene biguanide (PHMB) disc dressing group. Dressings were replaced every 7-days, or earlier, if clinically required. Participants were followed until device removal or hospital discharge. Feasibility outcomes included: proportion of potentially eligible participants who were enrolled; proportion of protocol violations; and proportion of patients lost to follow-up. Clinical outcomes were: CLABSI incidence, diagnosed by a blinded infection control practitioner; all cause BSI; and product-related adverse events. Findings: Of 143 patients screened, 101 (42%) were eligible. Five (3.5%) declined participation. There was one post-randomisation exclusion. Two (2%) protocol violations occurred in the CHG group. No patients were lost to follow-up. Three (3%) blood stream infections occurred; two (2%) were confirmed CLABSIs (one in each group) and one a mucosal barrier injury-related BSI. 1217 device days were studied; resulting in 1.64 CLABSI/1000 catheter days. One (1%) disc-related adverse events occurred in the CHG group. Conclusion: Disc dressings containg PHMB are safe to use for infection prevention at catheter insertion sites. An adequately powered trial to compare PHMB and CHG discs is feasible.

Details

Metrics

183 File views/ downloads
1026 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Infectious Diseases
Public, Environmental & Occupational Health

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image